{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T23:36:29Z","timestamp":1763681789411,"version":"3.45.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urolonc.2025.08.010","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:11:16Z","timestamp":1756984276000},"page":"710.e9-710.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of 68Ga-PSMA-11 PET\/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-5020","authenticated-orcid":false,"given":"U\u011furay","family":"Aydos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3792-0399","authenticated-orcid":false,"given":"Selahattin Bar\u0131\u015f","family":"K\u00fc\u00e7\u00fckali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-6741","authenticated-orcid":false,"given":"Erdem","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6270-3224","authenticated-orcid":false,"given":"Edanur","family":"Tun\u00e7ay \u0130bi\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-0863","authenticated-orcid":false,"given":"Seda","family":"G\u00fclbahar Ate\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-5870","authenticated-orcid":false,"given":"\u00dcmit \u00d6zg\u00fcr","family":"Akdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-656X","authenticated-orcid":false,"given":"L\u00fctfiye \u00d6zlem","family":"Atay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.08.010_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0002","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0003","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cncr.23293","article-title":"A nomogram predicting long-term biochemical recurrence after radical prostatectomy","volume":"112","author":"Suardi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0004","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0008","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0009","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"68 Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA< 0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0011","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","article-title":"Prospective comparison of whole-body MRI and 68 Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"46","author":"Sawicki","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18 F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109556","article-title":"PSMA PET\/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: comparison of detection rates and therapeutic implications","volume":"136","author":"Morawitz","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0014","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68 Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2214\/AJR.14.14275","article-title":"Detection of local recurrence of prostate cancer after radical prostatectomy using endorectal coil MRI at 3 T: addition of DWI and dynamic contrast enhancement to T2-weighted MRI","volume":"205","author":"Kitajima","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-017-3850-x","article-title":"Clinical performance of 68 Ga-PSMA-11 PET\/MRI for the detection of recurrent prostate cancer following radical prostatectomy","volume":"45","author":"Kranzb\u00fchler","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0017","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.118.225276","article-title":"Detection rate and localization of prostate cancer recurrence using 68Ga-PSMA-11 PET\/MRI in patients with low PSA values\u2264 0.5 ng\/mL","volume":"61","author":"Kranzb\u00fchler","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0018","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1007\/s00330-023-10442-4","article-title":"Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET\/MRI","volume":"34","author":"Jannusch","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0019","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","article-title":"Comparison of PET\/CT and PET\/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11307-019-01424-4","article-title":"Whole-body integrated [68 Ga] PSMA-11-PET\/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET\/CT as the standard of reference","volume":"22","author":"Guberina","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0021","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen\u2013ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00259-019-04505-2","article-title":"Prediction nomogram for 68 Ga-PSMA-11 PET\/CT in different clinical settings of PSA failure after radical treatment for prostate cancer","volume":"47","author":"Ceci","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0023","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2967\/jnumed.121.262347","article-title":"Predictors of 18F-DCFPyL PET\/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy","volume":"63","author":"Mena","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0024","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/MNM.0000000000001591","article-title":"Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET\/CT due to biochemical recurrence","volume":"43","author":"Coskun","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.acra.2023.09.002","article-title":"Predicting 18F-DCFPyL-PET\/CT scan positivity in prostate cancer patients with biochemical recurrence","volume":"31","author":"Lee","year":"2024","journal-title":"Acad Radiol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0026","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0028","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostatespecific membrane antigen\u2013targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0031","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.121.262411","article-title":"The European Association of Urology biochemical recurrence risk groups predict findings on PSMA PET in patients with biochemically recurrent prostate cancer after radical prostatectomy","volume":"63","author":"Dong","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0032","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2967\/jnumed.121.262821","article-title":"PSMA PET validates higher rates of metastatic disease for European Association of Urology biochemical recurrence risk groups: an international multicenter study","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0033","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0034","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1118\/1.4945416","article-title":"NEMA NU 2-2012 performance studies for the SiPMbased ToF-PET component of the GE SIGNA PET\/MR system","volume":"43","author":"Grant","year":"2016","journal-title":"Med Phys"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzb\u00fchler","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-016-0233-4","article-title":"Impact of 68 Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy","volume":"6","author":"Bluemel","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.urolonc.2025.08.010_bib0037","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12094-017-1736-9","article-title":"The feasibility of prostate-specific membrane antigen positron emission tomography (PSMA PET\/CT)-guided radiotherapy in oligometastatic prostate cancer patients","volume":"20","author":"Guler","year":"2018","journal-title":"Clin Transl Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T23:18:49Z","timestamp":1763680729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1078143925003151"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic performance of 68Ga-PSMA-11 PET\/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}